Class Action Lawsuit Announced for MoonLake Investors
The law firm Robbins Geller Rudman & Dowd LLP has announced an opportunity for investors who have incurred substantial losses in MoonLake Immunotherapeutics (NASDAQ: MLTX) to participate in a class action lawsuit. This legal initiative, titled Bridgewood v. MoonLake Immunotherapeutics, is filed in the Southern District of New York and aims to represent shareholders who acquired common stock in the company during the class period. The lawsuit claims that MoonLake and several of its executives violated the Securities Exchange Act of 1934 through misleading statements regarding their promising drug candidate, sonelokimab (“SLK”).
Allegations Against MoonLake
The crux of the lawsuit centers on allegations that the defendants made false representations about the efficacy of SLK in treating hidradenitis suppurativa (“HS”), a chronic inflammatory skin condition. According to the complaint, essential claims regarding SLK’s advantages over Union Chimique Belge’s BIMZELX—a previously approved treatment—were significantly overstated. The allegations suggest that both drugs target the same inflammatory cytokines, namely IL-17A and IL-17F, and that SLK’s unique Nanobody structure would not yield a clinical benefit over BIMZELX’s traditional monoclonal antibody design.
The complaint highlights a particularly damaging announcement made by the company on September 28, 2025, when it revealed that SLK’s 16-week results from its Phase 3 VELA program failed to demonstrate competitive efficacy compared to BIMZELX. Following this revelation, MoonLake‘s stock price plummeted by nearly 90%, significantly impacting investors’ portfolios.
Lead Plaintiff Process and Legal Representation
Investors who believe they qualify to act as lead plaintiffs in this class action are encouraged to submit their information by December 15, 2025. The process is governed by the Private Securities Litigation Reform Act of 1995, which allows individuals with the greatest financial stake in the case to represent the broader class of affected investors. Those interested in pursuing this opportunity can contact attorneys J.C. Sanchez or Jennifer N. Caringal at Robbins Geller via telephone or email.
It’s important to note that being appointed as lead plaintiff does not limit an investor’s ability to share in any potential settlements that may arise from the lawsuit, allowing them to have a significant role while still benefiting from any collective recovery.
About Robbins Geller
Robbins Geller Rudman & Dowd LLP is recognized as a leading firm in securities litigation, having secured substantial monetary relief for investors over the years. The firm boasts a strong track record, including recovering over $2.5 billion in 2024 for clients in securities-related class action cases. With a considerable number of attorneys spread across ten offices, Robbins Geller remains one of the largest and most prominent plaintiffs’ firms globally, demonstrating its commitment to protecting investor rights. For more detailed information on their services and past successes, interested parties can visit their official website.
Related
